WCN24-2548 SHORT-TERM OUTCOMES WITH NO TAPERING TACROLIMUS TO BELATACEPT CONVERSION IN RENAL TRANSPLANT RECIPIENTS (RTRs)

WCN24-2548 SHORT-TERM OUTCOMES WITH NO TAPERING TACROLIMUS TO BELATACEPT CONVERSION IN RENAL TRANSPLANT RECIPIENTS (RTRs)

Saved in:

Bibliographic Details
Main Authors:	Adela Mattiazzi, Katherine Balloveras, Pierina Cabrera, Tiffany Uhlyar, Naomi Pierre, Alejandra Centeno
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924011306
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients
by: Orhan Efe, et al.
Published: (2024-12-01)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
by: Shruti Gupta, et al.
Published: (2018-01-01)

One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients
by: Charlotte Duneton, et al.
Published: (2025-06-01)

Belatacept Conversion in Adolescent Kidney Transplant Recipients: A Solution for the Critical Challenge of Adherence?
by: Dominique Bertrand
Published: (2025-06-01)

From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept
by: Quentin Perrier, et al.
Published: (2024-04-01)

RTRS algorithm in low-power Internet of things
by: Yuchen CHEN, et al.
Published: (2019-12-01)

RTRS algorithm in low-power Internet of things
by: Yuchen CHEN, et al.
Published: (2019-12-01)

Belatacept-based immunosuppression in heart transplant recipients: A single center experience
by: Wairimu Magua, PhD, MS, et al.
Published: (2025-08-01)

Similar Efficacy in Belatacept-Converted Kidney Transplant Recipients With Steroid-Avoiding Regimen
by: Nathalie Chavarot, et al.
Published: (2025-03-01)

The Conversion From Mycophenolic Acid to Mammalian Target of Rapamycin Inhibitor Reduces the Incidence of Cytomegalovirus Replication in Belatacept-Treated Kidney-Transplant Recipients
by: Arnaud Del Bello, et al.
Published: (2024-06-01)

WCN25-2548 Role of therapy and predictors retarding disease progression in biopsied CKD patients: An observational study
by: Sourya Sourabh Mohakuda, et al.
Published: (2025-02-01)

WCN25-3049 BELATACEPT -THE NEED OF THE HOUR IN INDIA !
by: Jatin Kothari, et al.
Published: (2025-02-01)

BELATACEPT IN RENAL TRANSPLANTATION
by: A. I. Sushkov, et al.
Published: (2013-03-01)

Intrapatient tacrolimus variability is associated with medical nonadherence among pediatric kidney transplant recipients
by: Tara B. Gavcovich, et al.
Published: (2025-03-01)

WCN24-1499 TACROLIMUS-INDUCED HYPOMAGNESEMIA IN A KIDNEY TRANSPLANT RECIPIENT
by: Wanprapit Noree, et al.
Published: (2024-04-01)

The use of belatacept in kidney transplantation
by: N. N. Babenko, et al.
Published: (2018-09-01)

Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
by: Julie Belliere, et al.
Published: (2014-01-01)

Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
by: Lars Pape, et al.
Published: (2011-01-01)

Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study
by: Dominique Bertrand, et al.
Published: (2024-12-01)

Patiromer Does Not Alter Tacrolimus Pharmacokinetics in Kidney Transplant Recipients When Administered Three Hours Post–Tacrolimus
by: Ole Martin Drevland, MSc, et al.
Published: (2024-12-01)

Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus
by: V. E. Syutkin, et al.
Published: (2021-09-01)

Assessing drug-drug interactions of Tacrolimus with Fluconazole and/or Verapamil and developing the predictive model for Tacrolimus concentrations in kidney transplant recipients
by: Mingkwan Na Takuathung, et al.
Published: (2025-06-01)

Treatment of Acute Tacrolimus Toxicity with Phenytoin in Solid Organ Transplant Recipients
by: Arin S. Jantz, et al.
Published: (2013-01-01)

Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective
by: Hany M. El Hennawy, et al.
Published: (2025-08-01)

Evaluation of Torque Teno Virus DNA Load as a Predictive Biomarker in Kidney Transplant Recipients Converted from Calcineurin Inhibitors to Belatacept
by: Lara Cabezas, et al.
Published: (2024-06-01)

WCN25-2900 CYP3A5 POLYMORPHISM AND TACROLIMUS CONCENTRATION IN INDIAN RENAL TRANSPLANT RECIPIENTS
by: Shreyas Akki, et al.
Published: (2025-02-01)

P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES
by: CAMILO ANDRES TORRES LONDOÑO, et al.
Published: (2024-12-01)

CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
by: Marcos V. Silva, et al.
Published: (2012-01-01)

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future
by: Johan Noble, et al.
Published: (2025-05-01)

Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database.
by: Wida S Cherikh, et al.
Published: (2025-01-01)

The association between serum tacrolimus concentrations and BK viruria in kidney transplant recipients
by: Napatsorn Kraivisitkul, et al.
Published: (2025-01-01)

Population dynamics analysis of the interaction between tacrolimus and voriconazole in renal transplant recipients
by: Zhi-Hua Sun, et al.
Published: (2025-01-01)

CONVERSION TO TACROLIMUS IN PATIENTS WITH LATE ACUTE AND CHRONIC REJECTION OF TRANSPLANTED KIDNEY
by: E. S. Stolyarevich, et al.
Published: (2011-06-01)

Personalized dosing protocol for extended-release tacrolimus in kidney transplant recipients in the early postoperative period
by: A. V. Shabunin, et al.
Published: (2023-04-01)

Effect of tacrolimus formulation on neurocognition in older kidney transplant recipients: A randomized controlled trial
by: Hadia Lala Gul, et al.
Published: (2025-09-01)

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19
by: Han Yan, et al.
Published: (2025-01-01)

HEMOFILTRATION AND COUPLED PLASMA FILTRATION ADSORPTION IMPACT ON TACROLIMUS BLOOD CONCENTRATION IN RENAL TRANSPLANT RECIPIENTS
by: A.V. Vatazin, et al.
Published: (2014-05-01)

A rare but important adverse effect of tacrolimus in a heart transplant recipient: diabetic ketoacidosis
by: Zeynelabidin Öztürk, et al.
Published: (2015-10-01)

Tacrolimus Toxicity in Two Renal Transplant Recipients Treated With Nirmatrelvir/Ritonavir: A Case Series
by: Meaghan Coyne, et al.
Published: (2023-03-01)

Correlation between insulin-like growth factor 1 levels and tacrolimus dose in pediatric liver recipients
by: R. M. Kurabekova, et al.
Published: (2021-07-01)